These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38867845)

  • 1. Once-weekly insulin icodec versus once-daily long-acting insulins for type 2 diabetes mellitus: Systematic review and meta-analysis.
    Ribeiro SAG; Chavez MP; Hespanhol LC; Almeida Balieiro CC; Paqualotto E; Ribeiro E Silva R; Gauza M; Roberto de Sa J
    Metabol Open; 2024 Jun; 22():100285. PubMed ID: 38867845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once-Weekly Insulin Icodec in Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Clinical Trials (ONWARDS Clinical Program).
    Lisco G; De Tullio A; De Geronimo V; Giagulli VA; Guastamacchia E; Piazzolla G; Disoteo OE; Triggiani V
    Biomedicines; 2024 Aug; 12(8):. PubMed ID: 39200316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-weekly Insulin Icodec as Compared to Once-daily Basal Insulins: A Meta-analysis.
    Mukhopadhyay P; Chatterjee P; Pandit K; Sanyal D; Ghosh S
    Endocr Pract; 2024 Feb; 30(2):128-134. PubMed ID: 37984730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-weekly Insulin Icodec Versus Once-daily Long-acting Insulin for Type II Diabetes: A Meta-analysis of Randomized Controlled Trials.
    Abuelazm M; Ibrahim AA; Khlidj Y; Badr A; Amin AM; Elzeftawy MA; Gowaily I; Elsaeidy AS; Abdelazeem B
    J Endocr Soc; 2024 Jan; 8(2):bvad177. PubMed ID: 38213906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of once-weekly insulin icodec in type 2 diabetes: A meta-analysis of ONWARDS phase 3 randomized controlled trials.
    Shetty S; Suvarna R
    Diabetes Obes Metab; 2024 Mar; 26(3):1069-1081. PubMed ID: 38192022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Outcomes With Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Insulin-Naïve and Previously Insulin-Treated Individuals With Type 2 Diabetes: A Meta-Analysis of Randomised Controlled Trials.
    Ahmed M; Shafiq A; Javaid H; Jain H; Nashwan AJ; Tul-Ain Q; Basit J
    Endocrinol Diabetes Metab; 2024 May; 7(3):e00480. PubMed ID: 38659132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-Weekly Insulin Icodec
    Ribeiro E Silva R; de Miranda Gauza M; Guisso MES; da Silva JON; Kohara SK
    Arch Endocrinol Metab; 2023 May; 67(5):e000614. PubMed ID: 37249450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial.
    Lingvay I; Asong M; Desouza C; Gourdy P; Kar S; Vianna A; Vilsbøll T; Vinther S; Mu Y
    JAMA; 2023 Jul; 330(3):228-237. PubMed ID: 37354562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial.
    Philis-Tsimikas A; Asong M; Franek E; Jia T; Rosenstock J; Stachlewska K; Watada H; Kellerer M
    Lancet Diabetes Endocrinol; 2023 Jun; 11(6):414-425. PubMed ID: 37148899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of once-weekly insulin icodec compared to once-daily insulin g U-100 in patients with type II diabetes: a systematic review and meta-analysis.
    Saleem SZ; Fareed A; Akhtar SMM; Farhat S; Taha AM; Akilimali A
    Diabetol Metab Syndr; 2024 Apr; 16(1):80. PubMed ID: 38566252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial.
    Bajaj HS; Bergenstal RM; Christoffersen A; Davies MJ; Gowda A; Isendahl J; Lingvay I; Senior PA; Silver RJ; Trevisan R; Rosenstock J
    Diabetes Care; 2021 Jul; 44(7):1586-1594. PubMed ID: 33875485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial.
    Mathieu C; Ásbjörnsdóttir B; Bajaj HS; Lane W; Matos ALSA; Murthy S; Stachlewska K; Rosenstock J
    Lancet; 2023 Jun; 401(10392):1929-1940. PubMed ID: 37156252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-weekly basal insulin icodec: Looking ONWARDS from pharmacology to clinical trials.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2022 Sep; 16(9):102615. PubMed ID: 36108418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous glucose monitoring-based metrics and the duration of hypoglycaemia events with once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-naive type 2 diabetes: an exploratory analysis of ONWARDS 1.
    Bergenstal RM; Ásbjörnsdóttir B; Watt SK; Lingvay I; Mader JK; Nishida T; Rosenstock J
    Lancet Diabetes Endocrinol; 2024 Nov; 12(11):799-810. PubMed ID: 39374601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the efficacy and safety of weekly Insulin Icodec vs. Daily Insulin Glargine in type 2 Diabetes Mellitus: a systematic review and meta-analysis.
    Zuhair V; Obaid MA; Mustafa MS; Shafique MA; Rangwala BS; Shakil A; Babar A; Rangwala HS; Obaid MI
    J Diabetes Metab Disord; 2024 Jun; 23(1):1337-1349. PubMed ID: 38932816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous Glucose Monitoring-Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-standing Type 2 Diabetes Switched From a Daily Basal Insulin to Once-Weekly Insulin Icodec: Post Hoc Analysis of ONWARDS 2 and ONWARDS 4.
    Bajaj HS; Ásbjörnsdóttir B; Carstensen L; Laugesen C; Mathieu C; Philis-Tsimikas A; Battelino T
    Diabetes Care; 2024 Apr; 47(4):729-738. PubMed ID: 38380954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Once-Weekly Insulin Regimes on Glycemic Control for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
    Wang P; Zhang Y; Xu W; He J; Peng L; Feng Y; Xu P; Chong W; Hai Y; Jia L; Fang F
    Diabetol Metab Syndr; 2024 Jan; 16(1):3. PubMed ID: 38172995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Icodec: A Novel Once-Weekly Basal Insulin for Diabetes Management.
    Goldman J; Triplitt C; Isaacs D
    Ann Pharmacother; 2024 Oct; ():10600280241287790. PubMed ID: 39425483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial.
    Russell-Jones D; Babazono T; Cailleteau R; Engberg S; Irace C; Kjaersgaard MIS; Mathieu C; Rosenstock J; Woo V; Klonoff DC
    Lancet; 2023 Nov; 402(10413):1636-1647. PubMed ID: 37863084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-weekly insulin icodec compared with daily basal insulin analogues in type 2 diabetes: Participant-level meta-analysis of the ONWARDS 1-5 trials.
    Bajaj HS; Ásbjörnsdóttir B; Bari TJ; Begtrup K; Vilsbøll T; Rosenstock J
    Diabetes Obes Metab; 2024 Sep; 26(9):3810-3820. PubMed ID: 38951942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.